WHO-GMP for Ophthalmic Manufacturing: What the Standard Actually Requires

Ask any hospital purchase committee what they look for in an eye drop supplier, and "WHO-GMP certified" will appear near the top of the list. Yet the phrase is often used loosely — as a badge rather than a system. WHO Good Manufacturing Practices are not a certificate on a wall; they are a complete operating discipline covering premises, people, processes, water, air, documentation and quality control. For sterile ophthalmic products, where a single contaminated batch can cause sight-threatening infection, the requirements are among the most demanding in all of pharmaceutical manufacturing.

This article explains what WHO-GMP actually requires of an eye drop manufacturer in India today — and how the revised Schedule M, notified on 28 December 2023 (GSR 922(E)), has hard-wired those expectations into Indian law.

What WHO-GMP Is — and How It Reached Indian Law

WHO has published GMP guidelines through its Technical Report Series (TRS) for decades. For sterile products, the key modern reference is WHO TRS No. 1044, Annex 2: "WHO good manufacturing practices for sterile pharmaceutical products" — the document that Indian regulators explicitly point manufacturers toward.

India's domestic GMP baseline is Schedule M of the Drugs and Cosmetics Rules, 1945. The revised Schedule M notified in December 2023 rewrote the sterile products chapter (Part II: "Specific requirements for manufacture of sterile products, parenteral preparations and sterile ophthalmic preparations") in line with TRS 1044 Annex 2. A subsequent DCGI circular in August 2024 directed all sterile product and vaccine manufacturers to perform gap analyses against the revised Schedule M and the WHO TRS guidelines, and to close those gaps. Compliance timelines were phased: six months for larger companies (turnover above ₹250 crore) and twelve months for smaller ones.

In short: for an Indian eye drop manufacturer, WHO-GMP is no longer an aspiration — it is the enforceable legal standard.

The Core Principle: Sterility Cannot Be Tested Into a Product

Every GMP framework for sterile products rests on one idea: a sterility test samples only a tiny fraction of a batch, so passing it proves nothing by itself. Sterility must be built into the process — through facility design, environmental control, validated sterilisation and disciplined aseptic behaviour. Everything in WHO-GMP for ophthalmics flows from this principle.

Facility and Cleanroom Requirements

Zoned, classified environments

Manufacturing areas must be divided into clearly separated zones — support areas (washing, component preparation), preparation areas (bulk compounding), change areas, and the aseptic core. Air cleanliness is controlled by grade:

• Grade A — the critical zone where open product, open containers and exposed sterilised components are handled (e.g. the filling point). Unidirectional airflow, continuous particle monitoring.
• Grade B — the background environment immediately surrounding Grade A for aseptic operations.
• Grades C and D — supporting activities such as solution preparation and component handling, with defined particle and microbial limits.

Pressure cascades keep air flowing from cleaner to less clean areas; doors are interlocked; surfaces are smooth, non-shedding and cleanable.

HVAC and water systems

Two utilities make or break an ophthalmic plant:

• HVAC: HEPA-filtered air supply with validated air-change rates, temperature and humidity control, and continuous differential pressure monitoring between zones.
• Water: Purified Water and Water for Injection (WFI) systems designed, sanitised and monitored to keep chemical and microbial quality within pharmacopoeial limits. Eye drops are mostly water — the water system is the product.

The Contamination Control Strategy (CCS)

The single biggest conceptual addition in the revised Schedule M — mirroring WHO TRS 1044 Annex 2 and EU GMP Annex 1 (2022) — is the mandatory, documented Contamination Control Strategy. The CCS is a facility-wide master plan that identifies every potential route by which contamination could reach the product, and documents the control for each:

• Personnel (gowning, training, aseptic behaviour, health monitoring)
• Environment (cleanroom classification, environmental monitoring programme)
• Equipment (cleaning, sterilisation, maintenance, calibration)
• Materials (incoming component control, bioburden limits, de-cartoning and transfer)
• Process (sterilising filtration, aseptic connections, hold times, interventions)

The CCS is a living document, reviewed against trending data from environmental monitoring, media fills and deviations. Inspectors increasingly ask for it by name.

Aseptic Processing and Media Fills

Most eye drops are manufactured by aseptic processing: the bulk solution is sterilised by filtration through a validated 0.22 µm sterilising-grade filter into pre-sterilised containers, and filled and sealed in the Grade A/B aseptic core. Because the product itself is never terminally sterilised in its final container, the process must be periodically proven through media fills (aseptic process simulations):

• The entire filling line is run with sterile growth medium instead of product, under worst-case conditions — maximum duration, all permitted interventions, full operator complement.
• Filled units are incubated; any growth indicates a loss of asepsis and triggers investigation and requalification.
• Under the revised Schedule M, media fill frequency is risk-based rather than a fixed twice-yearly ritual, and the number of units filled must reflect actual production scale.

Where a product and its container permit, terminal sterilisation of the filled container is preferred over aseptic processing, because it provides a far higher sterility assurance level. Packaging innovations such as blow-fill-seal (BFS) technology — where the container is formed, filled and sealed in one continuous automated operation inside a controlled environment — dramatically reduce human intervention and are widely regarded as best practice for unit-dose ophthalmics.

Barrier technology deserves a mention here. The revised Schedule M now includes dedicated requirements for isolators and RABS (restricted access barrier systems) — validated bio-decontamination cycles, glove-integrity testing programmes and defined transfer processes — recognising that physical separation of the operator from the critical zone is the strongest contamination control available. For a buyer reading a manufacturer's documentation, the presence (or absence) of barrier technology on the filling line is a useful proxy for how seriously sterility assurance is engineered.

Quality Control: The Laboratory Backbone

The revised Schedule M also modernised QC laboratory expectations:

• Dedicated, environmentally controlled instrument rooms; a separate microbiology laboratory (BSL-2 level); HEPA-filtered laminar airflow for sterility testing.
• Stability studies following ICH Q1A–Q1F protocols, including photostability (ICH Q1B) and mandatory container-closure integrity testing.
• Defined qualification and requalification of reference standards, with proper Certificates of Analysis.

For ophthalmic products specifically, the QC suite covers sterility, particulate matter, preservative content and efficacy, pH, osmolality, viscosity, fill volume and — critically — the stability-indicating assay of the active ingredient across shelf life.

Data Integrity and the Pharmaceutical Quality System

Two further expectations now permeate inspections:

• ALCOA+ data integrity — records must be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring and Available. Audit trails on electronic systems, unique user access, and review of raw data are all in scope.
• Lifecycle validation — process validation is no longer "three batches and done". It runs in three stages (process design, process qualification, continued process verification) for the life of the product, alongside an Annual Product Quality Review (APQR) covering every batch, deviation, complaint and stability result.

The Documentation Pack a Compliant Manufacturer Maintains

WHO-GMP compliance is provable on paper. A sterile ophthalmic manufacturer operating to the revised Schedule M should be able to produce, on request or inspection:

• Site Master File describing premises, systems and quality organisation
• Validation Master Plan covering qualification (DQ/IQ/OQ/PQ) of facilities, utilities and equipment, plus process and cleaning validation status
• Media fill records with incubation results and investigation of any positives
• Environmental monitoring trends with alert/action limit excursions and CAPA
• Water system reports — chemical and microbial, with sanitisation records
• Batch Manufacturing Records with full traceability from raw material lots to finished batch
• Stability protocols and reports per product, ICH Q1A-aligned
• Annual Product Quality Reviews for every marketed product
• Deviation, OOS, complaint and recall logs with root-cause analysis
• Self-inspection reports — the revised Schedule M formalises periodic internal GMP audits

The existence, currency and internal consistency of this pack is the difference between a certified plant and a compliant quality system.

What Buyers Should Take From This

For a distributor or hospital pharmacist, the practical translation is a set of questions to ask any manufacturer:

1. Do you have a documented Contamination Control Strategy for your sterile lines?
2. When was your last media fill, and what were the results?
3. What are your cleanroom grades at the filling point, and how is monitoring trended?
4. Can we see your stability programme design (ICH Q1A) and container-closure integrity data?
5. Which pharmacopoeia do your QC methods follow, and are your labs equipped for in-house microbiology?

A manufacturer operating to WHO-GMP — as Oculentis Medical does across products like Ocufina and the Restor lubricant family — will answer these without hesitation, because the answers are generated by the quality system itself.

Frequently Asked Questions

Is WHO-GMP certification legally required to make eye drops in India?

Indian law requires compliance with Schedule M of the Drugs and Cosmetics Rules, 1945. Since the December 2023 revision, Schedule M's sterile products chapter — which explicitly covers sterile ophthalmic preparations — is aligned with WHO TRS 1044 Annex 2. So while "WHO-GMP certification" as a document is issued by various certifying bodies, the substance of WHO-GMP is now a legal requirement enforced through Schedule M inspections.

What is a media fill and why does it matter?

A media fill (aseptic process simulation) replaces the product with sterile growth medium and runs the entire filling process under worst-case conditions. Incubating the filled units proves whether the aseptic process truly prevents contamination. It is the single most direct validation of sterility assurance for aseptically filled eye drops.

Why are most eye drops made aseptically instead of being terminally sterilised?

Many ophthalmic formulations and their plastic containers cannot tolerate the heat of terminal sterilisation without degrading the active ingredient or deforming the pack. Where terminal sterilisation is feasible it is preferred; otherwise, validated sterilising filtration plus aseptic filling is the accepted route — with correspondingly stricter environmental controls.

What changed for ophthalmic manufacturers under the revised Schedule M (2023)?

Key changes include a mandatory documented Contamination Control Strategy, risk-based media fill requirements, dedicated isolator/RABS provisions, modernised QC laboratory requirements, ICH-aligned stability studies with container-closure integrity testing, ALCOA+ data integrity expectations, lifecycle validation and a mandatory Annual Product Quality Review.

How can a buyer verify a manufacturer's GMP status?

Ask for the manufacturing licence, WHO-GMP certificate, the most recent regulatory inspection history, the CCS summary, media fill summaries and stability data for the specific products. Reputable manufacturers provide this documentation pack to distributors and institutional buyers as a matter of routine.

---

This article is a general educational overview of published GMP standards and Indian regulatory requirements, not a substitute for the official texts of Schedule M, WHO TRS 1044 or CDSCO guidance.

Want to partner with a WHO-GMP-aligned ophthalmic manufacturer? Become an Oculentis distributor or request product samples with full quality documentation.